Introduction
Advanced therapies are changing the treatment landscape for genetic disorders, cancers and conditions with limited treatment options. However, their scientific complexity creates regulatory challenges that conventional medicines do not always present. Manufacturing variability limited clinical populations, complex product characterisation and long-term safety considerations all influence development and approval.
In 2026, regulatory developments across the United States, European Union, India and Japan highlight how agencies are adapting their approaches to these therapies. For developers, understanding evolving ATMP regulatory requirements is essential for planning clinical evidence, manufacturing controls and market entry across multiple jurisdictions.
What are Advanced Therapy Medicinal Products (ATMPs)?
In the European Union, advanced therapy medicinal products (ATMPs) are medicines for human use based on gene therapy, somatic cell therapy or tissue engineering. Combined ATMPs incorporate qualifying medical devices or other components.
Although ATMP is an EU regulatory classification, other markets use different terminology and legal categories for cell and gene therapies and regenerative medicine products. These distinctions matter because classification determines the applicable development pathway, evidence requirements and authorisation process.
Why are ATMP Regulatory Requirements Evolving?
Regulatory frameworks are evolving alongside advances in gene editing, engineered cells, viral vectors and personalised treatments. Developers increasingly need to demonstrate not only clinical benefit but also product consistency, biological activity, manufacturing control and an appropriate strategy for monitoring delayed risks.
Recent developments illustrate this shift. In May 2026, the US FDA issued final guidance describing CMC flexibilities for eligible human cellular and gene therapy products being developed for biologics licence applications. India also expanded its centrally licensed approval framework for specified advanced cell and gene therapies in July 2026. These changes demonstrate growing regulatory attention to the specific characteristics of advanced therapies without removing the need to establish product quality, safety and efficacy.
How the European Union Regulates ATMPs
The EU ATMP regulatory framework is established principally under Regulation (EC) No 1394/2007, alongside applicable pharmaceutical legislation and quality, clinical and safety requirements.
The European Medicines Agency (EMA), through its Committee for Advanced Therapies (CAT), plays a central role in ATMP classification and scientific assessment. Marketing authorisation generally follows the centralised procedure, with the Committee for Medicinal Products for Human Use (CHMP) providing its opinion and the European Commission granting the authorisation.
Developers should address classification early, establish a suitable manufacturing and control strategy, generate relevant nonclinical and clinical evidence, and plan for traceability and post-authorisation monitoring. Hospital exemptions are a separate, narrowly defined national mechanism and should not be treated as a substitute for standard marketing authorisation.
The FDA's Approach to Cell and Gene Therapy Approvals
In the United States, the FDA regulates cell and gene therapy products primarily through the Center for Biologics Evaluation and Research (CBER). Depending on the product, developers may need an investigational new drug application before clinical trials and a biologics licence application for marketing.
The FDA’s guidance framework addresses chemistry, manufacturing and controls (CMC), pharmacology and toxicology services, clinical development, potency assessment and long-term safety. Its May 2026 final CMC guidance describes flexibility in how certain manufacturing requirements may be addressed during development of eligible products, while maintaining applicable statutory and regulatory standards.
This flexibility is not a blanket exemption from CMC requirements. Sponsors must justify their approach and demonstrate that product quality and patient safety remain adequately controlled.
ATMP Regulatory Approaches in Other Global Markets
Regulatory pathways differ across regions, making early market-specific planning important.
- Japan: The Pharmaceuticals and Medical Devices Agency (PMDA) and Ministry of Health, Labour and Welfare oversee regenerative medicine products. Japan provides conditional and time-limited approval under defined circumstances, subject to subsequent evidence requirements. Relevant approval documents were revised in March 2026.
- India: The July 2026 amendment to the Drugs Rules, 1945 expanded the Centrally Licensed Approving Authority framework to specified cell-derived products, gene therapeutics and xenografts. Sponsors should assess the applicable classification, licensing and evidence requirements for their individual products.
- United Kingdom: The Medicines and Healthcare products Regulatory Agency (MHRA) regulates relevant advanced therapies under the UK medicines framework. The Innovative Licensing and Access Pathway (ILAP) offers eligible products a structured route for regulatory and development support, but entry does not guarantee authorisation.
These approaches reflect different legal systems and development priorities. A pathway available in one market should not be assumed to apply in another.
Key Differences in Global ATMP Approval Requirements
The main differences concern product classification, clinical evidence, manufacturing expectations, authorisation routes and post-approval obligations.
| Regulatory Area | Key Consideration |
|---|---|
| Classification | Definitions and eligibility criteria differ by jurisdiction. |
| Clinical Evidence | Study design, endpoints and evidence expectations depend on the product and intended indication. |
| Manufacturing | CMC, potency, comparability and process controls require product-specific justification. |
| Authorisation | Standard, conditional and expedited pathways have different eligibility criteria. |
| Lifecycle Oversight | Traceability, pharmacovigilance and long-term follow-up depend on applicable rules and product risks. |
Global development therefore requires a consistent scientific strategy supported by region-specific regulatory planning.
How Regulators are addressing ATMP Development Challenges
Agencies are adapting guidance, consultation mechanisms and approval pathways to address the challenges of complex therapies. Examples include the FDA’s CMC flexibility guidance, the EU’s specialised ATMP assessment structure and Japan’s conditional and time-limited approval mechanism.
These approaches can support development where conventional evidence-generation models are difficult to apply. However, flexibility does not eliminate the need for a scientifically justified benefit–risk assessment, reliable manufacturing processes or appropriate post-authorisation evidence.
Common Regulatory Challenges for ATMP Developers
Developers commonly face challenges in demonstrating potency, maintaining manufacturing consistency, establishing comparability after process changes and generating sufficient clinical evidence in small patient populations.
Autologous products add patient-specific manufacturing and chain-of-identity considerations. Gene therapies may require assessment of biodistribution, shedding, immunogenicity and potential delayed risks, depending on the product. These issues can affect study design, dossier preparation and post-approval commitments.
How Companies can prepare for Global ATMP Approvals
A coordinated regulatory strategy should begin during early development.
- Confirm product classification and applicable pathways in each target market.
- Align nonclinical, clinical and CMC development plans with intended regulatory claims.
- Establish suitable potency assays, specifications, process controls and comparability strategies.
- Plan for region-specific submission requirements, traceability and long-term safety monitoring.
- Engage regulators early when scientific advice or pre-submission consultation is available.
- Maintain regulatory intelligence to track changes that may affect development and market access.
Early alignment helps identify evidence gaps before they become costly submission or lifecycle issues.
How Regulatory Affairs Consulting Supports ATMP Development
Advanced therapy programmes require coordination across regulatory strategy, clinical development, manufacturing documentation and pharmacovigilance. Regulatory affairs consulting can help companies interpret jurisdiction-specific requirements, plan submissions, identify compliance gaps and maintain alignment as guidance evolves.
DDReg can support relevant regulatory planning, submission documentation, regulatory intelligence and pharmacovigilance activities across the product lifecycle. For ATMP developers, the value lies in connecting global regulatory expectations with practical development and compliance plans, while ensuring that specialised scientific or manufacturing activities are supported by appropriately qualified expertise.
Conclusion
ATMP regulatory requirements continue to evolve as global agencies respond to advances in cell and gene therapy. The 2026 developments in the United States, India and Japan, alongside the established EU framework, reinforce the importance of product-specific evidence, robust manufacturing controls and lifecycle planning.
For developers, successful global approval depends on understanding both the common scientific principles and the regulatory differences between markets. A coordinated strategy, supported by current regulatory intelligence and well-prepared documentation, can help address compliance risks and support a more predictable path from development to patient access.
Frequently Asked Questions
ATMP regulatory requirements cover product classification, manufacturing quality, nonclinical and clinical evidence, marketing authorisation and post-approval obligations. The specific requirements depend on the jurisdiction, product type and intended use.
The EU regulates ATMPs under a specialised legislative framework, principally Regulation (EC) No 1394/2007. The EMA's CAT supports classification and assessment, while marketing authorisation generally follows the centralised procedure.
The EMA operates within the EU ATMP framework, whereas the FDA regulates relevant products under US biologics and other applicable legislation. Classification, submission routes, evidence expectations and post-authorisation requirements may differ.
Evidence generally covers product quality, manufacturing controls, nonclinical safety, clinical safety and efficacy, and benefit–risk assessment. Additional evidence may address potency, biodistribution, shedding, immunogenicity and long-term risks where relevant.
Key challenges include variable starting materials, process consistency, potency testing, product characterisation, comparability after manufacturing changes, and establishing suitable release specifications and stability controls.
Long-term monitoring may be required, particularly for therapies with potential delayed or persistent effects. The duration and methods depend on the product's risk profile and applicable regulatory requirements.
Companies should map each market's classification and authorisation pathway, align core evidence-generation plans, identify regional differences, engage regulators early and maintain a coordinated regulatory intelligence process.
Resources:
- https://health.ec.europa.eu/medicinal-products/product-types/advanced-therapies_en
- https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-controls-flexibilities-developing-human-cellular-and-gene-therapy
- https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/cellular-gene-therapy-guidances
- https://www.pmda.go.jp/english/review services/reviews/0003.html
- https://www.gov.uk/government/publications/innovative-licensing-and-access-pathway-ilap